Evidence map›Paper›PMID 38718189›Full record

ArticleBioinformatics (Oxford, England)2022

From cell lines to cancer patients: personalized drug synergy prediction.

Halil Ibrahim Kuru, A Ercument Cicek, Oznur Tastan

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Knowledgeable Language Models as Black-Box Optimizers for Personalized Medicine.... International Conference on Learning Representations · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Unsupervised cell line embedding using pairwise drug response correlation.Computational and structural biotechnology journal · 2025
    Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Halil Ibrahim KuruDepartment of Computer Engineering, Bilkent University, Ankara 06800, Turkey.ORCID 0000-0003-4356-8846
A Ercument CicekDepartment of Computer Engineering, Bilkent University, Ankara 06800, Turkey.ORCID 0000-0001-8613-6619
Oznur TastanFaculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey.ORCID 0000-0001-7058-5372

Funding

TUBA-GEBIP 2017
6 · The paper itself

Abstract

motivationCombination drug therapies are effective treatments for cancer. However, the genetic heterogeneity of the patients and exponentially large space of drug pairings pose significant challenges for finding the right combination for a specific patient. Current in silico prediction methods can be instrumental in reducing the vast number of candidate drug combinations. However, existing powerful methods are trained with cancer cell line gene expression data, which limits their applicability in clinical settings. While synergy measurements on cell line models are available at large scale, patient-derived samples are too few to train a complex model. On the other hand, patient-specific single-drug response data are relatively more available.

resultsIn this work, we propose a deep learning framework, Personalized Deep Synergy Predictor (PDSP), that enables us to use the patient-specific single drug response data for customizing patient drug synergy predictions. PDSP is first trained to learn synergy scores of drug pairs and their single drug responses for a given cell line using drug structures and large scale cell line gene expression data. Then, the model is fine-tuned for patients with their patient gene expression data and associated single drug response measured on the patient ex vivo samples. In this study, we evaluate PDSP on data from three leukemia patients and observe that it improves the prediction accuracy by 27% compared to models trained on cancer cell line data. AVAILABILITY AND IMPLEMENTATION: PDSP is available at https://github.com/hikuru/PDSP.

Identifiers

PMID38718189
PMCPMC11215552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.